ESMO 2019: Merck unveils neoadjuvant/adjuvant TNBC trial results - 1 views
-
jacob logan on 04 Oct 19A regimen of neoadjuvant Keytruda and chemotherapy extended pathological complete response (pCR) rates by 13.6% compared to chemotherapy alone in patients with early triple-negative breast cancer (TNBC), according to findings from the Phase III Keynote-522 study presented at the ESMO Congress 2019.